What Katalyze AI does

Katalyze AI is a San Francisco-based, venture-backed company building an agentic AI operating system for pharmaceutical manufacturing. The platform unifies fragmented production data from MES, LIMS, historian, and quality systems into a single source-grounded record and deploys domain-trained agents to automate deviation investigations, batch release support, raw material quality management, and process optimization. Core products include the Katalyze AI Platform, the Katalyst AI agent, the Digityze AI digital transformation module, and the Raw Materials AI module, supported by Bio-AI models trained on accredited raw material databases and digital twin technology for both raw materials and processes. The company positions every agent output with GxP traceability by anchoring outputs back to original source records, which is a structural requirement for regulated pharma deployments.

The business operates on an enterprise SaaS model with quote-based custom contracts, targeting the 20 largest pharmaceutical companies globally. Go-to-market is consultative and field-driven, with a "Book a Demo" conversion path and content marketing through a knowledge center, podcasts, blog, and newsroom. Katalyze reports adoption by five of the 20 largest pharmaceutical companies and claims documented outcomes including reduction of deviation investigation time from approximately one year and $4-6M in cost to 45 minutes, 2x faster resolution than human analysts, and up to 8% yield uplift through digital twin-driven process optimization.

The company was founded circa 2024 by Reza Farahani (Founder and CEO), appointed Hannes Bretschneider as Chief AI Officer in December 2025 to lead the agentic AI architecture, launched the Katalyst product in January 2026, and closed a $10.5M seed round led by Bonfire Ventures in June 2026. Headcount is in the 11-50 range. The company is private and headquartered in San Francisco, California.

Name

Katalyze AI

Legal name

Katalyze AI

Website

https://KatalyzeAI.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Katalyze AI is a San Francisco-based startup building an agentic AI platform that unifies pharmaceutical manufacturing data and automates deviation investigations and process optimization for large pharma companies under GxP compliance requirements.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing AI Software

NAICS

Computer Systems Design Services (541512), Computer Systems Design and Related Services (54151)

SIC

Services-Computer Integrated Systems Design (7373)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

AI Integration & Orchestration Platforms (Connectors, Workflow, iPaaS for AI) (HDAEANAI), Audit, Explainability & Accountability Tooling (traceability, reporting) (HDAAAKAL)

Keywords

• Pharmaceutical manufacturing AI
• GxP compliance software
• Deviation investigation platform
• Biomanufacturing digital twin
• Agentic process automation

Headquarters

HQ city

Mountain View

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Enterprise SaaS Platform: AI-powered platform for pharmaceutical manufacturing with enterprise licensing model, likely subscription-based given the 'Book a Demo' sales motion and enterprise customer focus.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Katalyze AI builds a GxP-compliant agentic AI platform for pharmaceutical manufacturers that unifies data from MES, LIMS, historian, and quality systems and runs domain-trained AI agents to conduct deviation investigations, optimize processes, and analyze raw materials. The platform includes the Katalyst AI agent and modules such as Digityze AI and Raw Materials AI, supported by 40+ pre-built connectors for rapid deployment. It is sold to large pharmaceutical and biomanufacturing enterprises seeking to shorten deviation analyses, improve yields, and automate GxP-traceable decision workflows.

Product overview

Katalyze AI offers a modular platform architecture anchored by the Katalyze AI Platform as the core GxP-compliant system. The platform integrates specialized AI agents including Katalyst for manufacturing intelligence, Digityze AI for digital transformation, and Raw Materials AI for material optimization. The platform features built-in modules for Process Improvement & Monitoring, Deviation Management & Batch Release, Tech Transfer & CMC, Supply Chain, and Traceability. With 40+ built-in connectors, the platform unifies data from MES, LIMS, historian, and quality systems into a single source-grounded record for pharmaceutical manufacturing operations.

Differentiator

Problem solved

Functional benefit

Brands

• Katalyst: AI agent designed for pharmaceutical manufacturing that integrates with existing production systems to enhance decision-making and operational reliability. The AI agent helps reduce manual analysis, improve yields, and prevent batch failures.
• Katalyze
• Katalyze Agents

Products and services

• Katalyze AI Platform The primary GxP-compliant agent platform for pharmaceutical manufacturing that unifies scattered production data and runs domain-trained AI agents to conduct deviation investigations and power process improvement for large pharma manufacturers.
• Katalyst Katalyst is an AI agent designed for pharmaceutical manufacturing that integrates with existing production systems to enhance decision-making and operational reliability, reducing manual analysis, improving yields, and preventing batch failures for large pharma manufacturers.
• Digityze AI Digityze AI is an AI-powered module within the Katalyze platform focused on digital transformation capabilities for pharmaceutical manufacturing operations, sold to large pharma manufacturers seeking to modernize their production environments.
• Raw Materials AI Raw Materials AI is a module within the Katalyze platform that provides insights on raw materials, leveraging Bio-AI models trained on accredited databases to optimize quality and minimize waste for pharmaceutical manufacturers.

Quantifiable outcome

• Deviation investigation time reduced from 2 weeks to 45 minutes
• +3 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• MasterControl: GxP-grade quality, manufacturing and compliance SaaS for life sciences. Competes in adjacent workflow slots (deviations, batch release, CAPA) that Katalyze's deviation-management agents are designed to augment.
• Dotmatics: Scientific R&D and process data platform for pharma/biotech, including bioprocess and CMC workflows. Similar go-to-market of selling AI/analytics on top of unified lab and manufacturing data to large pharma.
• TetraScience: Cloud-native data platform for pharma R&D and manufacturing that unifies ELN, LIMS and instrument data. Directly comparable as a pharma/biotech data unification + AI layer, though with stronger R&D vs manufacturing tilt.
• Benchling: Cloud platform for biotech R&D and process development that centralizes experimental and process data. Comparable vertical SaaS play for life sciences with AI features layered on top of a domain data model.

Emerging players

• Ginkgo Bioworks: Synthetic biology and biomanufacturing platform with its own AI-driven process optimization stack (Codebase/Foundry). Comparable as a vertically-specialized AI player in bioprocess and bio-manufacturing, though more upstream/synthetic biology than pharma manufacturing.

Broad incumbents

• Palantir Foundry: Enterprise data operating system with a meaningful pharma manufacturing footprint via Foundry/AIP. Competes for the same agentic-AI-on-manufacturing-data wedge but as part of a much broader platform, not a GxP-specialized product.
• Veeva Systems: Dominant SaaS provider for life sciences (Veeva Vault Manufacturing, Quality, etc.). Most relevant comparison as a vertically-specialized pharma SaaS incumbent whose data and quality systems are common integration targets for Katalyze.
• IQVIA: Global pharma services and data/AI platform with significant manufacturing and quality analytics offerings. Relevant incumbent competitor for enterprise pharma AI/data analytics budgets.
• Dassault Systèmes (BIOVIA): Enterprise PLM and life sciences software (BIOVIA) used by pharma for process development, quality and manufacturing. Competes for similar digital-twin and bioprocess optimization use cases inside a much broader 3DEXPERIENCE stack.
• Sartorius (BioAnalytical & Bioprocess): Major bioprocess equipment and data analytics vendor; comparable as a supplier of digital tools that sit on top of upstream bioprocess data — a related buyer/competitor dynamic for raw-materials and process digital twins.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/katalyzeai

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Katalyze AI